Broker’s take: RHB raises SGX target price but says valuation, dividends ‘still unexciting’
RHB Research raised its target price on Singapore Exchange (SGX) to S$10 from S$9.60.
Brokers’ take: Analysts cut DFI Retail Group target on lower earnings forecast
ANALYSTS have shaved their price targets for DFI Retail Group upon trimming their earnings estimates.
Brokers’ take: DBS cuts target for Parkway Life Reit after factoring in higher capex
DBS Group Research cut its target price on Parkway Life Real Estate Investment Trust (Reit) after taking into account higher capital expenditures...
Brokers’ take: Citi downgrades SIA to ‘neutral’ on higher cost assumptions
CITI Research is expecting Singapore Airlines’ (SIA) share price to remain under pressure heading into the final quarter of its financial year...
Brokers’ take: Proposed policy changes could drive cost savings for ComfortDelGro
SINGAPORE’S planned changes to its regulations for the point-to-point transport services sector are expected to be a boon for the taxi industry...
Brokers’ take: Analysts raise Frencken targets after earnings beat forecasts; bullish on recovery
ANALYSTS have raised their target prices on Frencken Group and maintained their “buy” recommendations after the group’s second-half results for 2023 beat...
Brokers’ take: Maybank downgrades PropNex to ‘hold’, sees limited upside as property deals slow
MAYBANK downgraded PropNex to “hold” from “buy” and lowered its target price by 18.3 per cent to S$0.94 from S$1.15, as it...
Brokers’ take: RHB downgrades Golden Agri to ‘neutral’ after earnings disappointment
RHB Research downgraded its call on Golden Agri-Resources to “neutral” from “buy”, while slightly lowering its price target to S$0.29 from S$0.30.
Brokers’ take: Maybank initiates ‘buy’ on optimism about Thomson Medical’s growth plans
MAYBANK initiated coverage on Thomson Medical with “buy” and a target price of S$0.08.
Brokers’ take: RHB downgrades Venture Corp to ‘neutral’ as muted near term priced in
RHB has downgraded Venture Corporation to “neutral” from “buy” as its lacklustre near-term outlook has already been priced in the share price...